Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer

被引：0
|
作者：
Kasper, S. [1 ]
Cheng, A-L. [2 ]
Overkamp, F. [3 ]
Rouyer, M. [4 ]
Foch, C. [5 ]
Lamy, F-X. [6 ]
Esser, R. [5 ]
Messinger, D. [7 ]
Rothe, V. [7 ]
Chen, W. [8 ]
Brodowicz, T. [9 ]
Zielinski, C. C. [10 ,11 ]
机构：
[1] Univ Hosp Essen, Westdeutsch Tumorzentrum, Med Oncol, Essen, Germany
[2] Natl Taiwan Univ, Ctr Canc, Dept Internal Med & Oncol, Taipei, Taiwan
[3] Oncologianova GmbH, Oncol, Recklinghausen, Germany
[4] Univ Bordeaux, Bordeaux PharmacoEpi, INSERM, CIC1401, Bordeaux, France
[5] Merck Healthcare KGaA, Oncol, Darmstadt, Germany
[6] Merck Healthcare KGaA, Global Epidemiol, Darmstadt, Germany
[7] Prometris GmbH, Biostat, Mannheim, Germany
[8] Merck Serono, Biostat, Shanghai, Peoples R China
[9] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria
[10] Vienna Gen Hosp, Ctr Comprehens Canc, Oncol, Vienna, Austria
[11] Med Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
584P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [22] Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Shen
    Chung, Ik-Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Sarholz, Barbara
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy
    Klein-Scory, S.
    Wahner, I.
    Maslova, M.
    Al-Sewaidi, Y.
    Pohl, M.
    Mika, T.
    Ladigan, S.
    Schroers, R.
    Baraniskin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S229 - S229
  • [24] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Kim, Sang-A
    Park, Hyejoo
    Kim, Kui-Jin
    Kim, Ji-Won
    Sung, Ji Hea
    Nam, Milang
    Lee, Ju Hyun
    Jung, Eun Hee
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    Lee, Keun-Wook
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [26] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [27] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Sang-A Kim
    Hyejoo Park
    Kui-Jin Kim
    Ji-Won Kim
    Ji Hea Sung
    Milang Nam
    Ju Hyun Lee
    Eun Hee Jung
    Koung Jin Suh
    Ji Yun Lee
    Se Hyun Kim
    Jeong-Ok Lee
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Soo-Mee Bang
    Jong Seok Lee
    Keun-Wook Lee
    Scientific Reports, 11
  • [28] Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer
    Milenkovic-Grisic, Ana-Marija
    Hayes, Siobhan
    Farrell, Colm
    Kuroki, Yoshihiro
    Bertolino, Mauro
    Venkatakrishnan, Karthik
    Girard, Pascal
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 1071 - 1081
  • [29] Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 38 - 38
  • [30] Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Fruth, Briant
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Greene, Claire
    O'Neil, Bert H.
    Atkins, James Norman
    Berry, Scott
    Polite, Blase N.
    O'Reilly, Eileen M.
    Goldberg, Richard M.
    Hochster, Howard S.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    El-Khoueiry, Anthony B.
    Watson, Peter
    Benson, Al B., III
    Mulkerin, Daniel L.
    Mayer, Robert J.
    Blanke, Charles
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2392 - 2401
12345